Sanara MedTech Sets New Revenue Records and Accelerates Growth in Q4 2025
Sanara MedTech, a leading provider of surgical solutions, recently announced its fourth-quarter and full-year 2025 earnings, showcasing impressive growth and records. In a conference call held on March 24, 2026, the company's President and Chief Executive Officer, Seth Yon, highlighted several key accomplishments.
One notable achievement was exceeding $100 million in net revenue for the first time in the company's history, with a total of $103.1 million generated for the full year 2025, representing a 19% year-over-year growth. This impressive performance was achieved while maintaining the size of their field sales team, with 40 representatives at the end of 2025.
The company's hybrid commercial model, which includes both field sales reps and a growing network of independent distributor partners, played a significant role in driving this success. This approach enabled them to raise awareness of their products and educate prospective surgeon customers on their benefits and clinical applications.
Sanara MedTech also drove significant improvements in its profitability profile, expanding gross margins by approximately 200 basis points to 93% for the full year 2025. The company achieved a notable operating leverage, with a $1.5 million or 80% reduction in net loss from continuing operations and a $7.9 million or 86% improvement in adjusted EBITDA, resulting in $17 million for the full year 2025.
Furthermore, the performance enabled the company to generate $6.8 million of cash provided by operations for the full year 2025, compared to $24,000 of cash used in operations for the same period in 2024.
When discussing the fourth quarter's net revenue performance, Yon noted that their team delivered solid commercial execution, generating net revenue of $27.5 million, representing a 5% year-over-year growth. The net revenue growth was largely driven by sales of soft tissue products, with modest contributions from sales of bone fusion products.
Interestingly, the fourth quarter's net revenue performance came in at the high end of both the preliminary range provided in their press release on January 23, 2026, as well as the expectations shared on their third-quarter earnings call in November 2025. Excluding $1.8 million of BIASURGE sales related to Hurricane Helene, the net revenue in the fourth quarter of 2025 increased by 13% year-over-year.
Sanara MedTech's performance demonstrates the fundamental strength of their surgical business and supports their recent strategic decision to focus resources and capabilities on the surgical market. As they enter 2026, the company is well-positioned for further growth and expansion, with a clear strategy in place.
